Skip to main content
. 2022 Oct 13;77(4):1228–1240. doi: 10.1002/hep.32746

FIGURE 1.

FIGURE 1

JAK2, the main target of pacritinib, correlates with fibrosis and portal hypertension in patients with cirrhosis. (A) Diagram of the pacritinib targets. (B) Heat map of the correlation among Jak2, Irak1, and Csf1r with genes associated to HSC activation and fibrosis. (C) Correlation of hepatic transcriptional levels of Col1a1 with Jak2, Irak1, and Csf1r. (D) Heat map of correlation among Jak2, Irak1, and Csf1r with surrogates of portal hypertension. (E) Hepatic transcriptional levels of Infgr and Il12. (F) Heat map of correlation among Jak2, Irak1, and Csf1r with Infgr and Il12. Data are shown as Spearman rank coefficient (Rs) and p value. APRI, platelet ratio index; Csf1r, colony‐stimulating factor 1 receptor; Col1a1, type I collagen; FIB‐4, fibrosis‐4 score; Gα, G protein alpha subunit; HSC, hepatic stellate cell; Ifngr, interferon‐gamma receptor; Il12r, interleukin‐12 receptor; Irak1, interleukin‐1 receptor‐associated kinase; JAK2, Janus kinase 2; TIPS, transjugular intrahepatic portosystemic shunt.